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Streptococci had embolization, in contrast to 11 out of 16 patients
with S. aureus endocarditis.
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REPLY
We thank Dr. Mansi for his comments and welcome the chance to
summarize the literature on this subject. Older studies published
prior to 1980 showed a high percentage of those with Staphylo-
coccal endocarditis sustaining embolic or neurological complica-
tions; however, no statistical comparisons with other organisms
were made (1–3). For the most part, recent studies have reported
no significant difference in the incidence of embolization among
different underlying infective organisms (4–9). However, two of
these studies did show a higher rate of embolic complications in
cases caused by Staphylococcus aureus as compared to Streptococcus
viridans (8,9). A large series of patients with left-sided endocarditis
showed that overall S. aureus endocarditis had an embolic rate
2.4-fold greater than that with S. viridans endocarditis (10). Other
investigators have reported a significant association between
Staphylococcal endocarditis and embolization in cases selected by
transesophageal echocardiography (11), where all neurological
complications were considered together (12,13), or where intra-
cranial hemorrhage alone was considered (14). Also, although the
reported incidence of embolization in fungal and enterococcal
endocarditis is high, numbers in any given series are small
(1–3,15).
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A Randomized Trial of Aspirin
on the Risk of Embolic Events
in Patients With Infective Endocarditis
We read with great interest the study by Chan et al. (1). We are
not surprised that high-dose aspirin (325 mg once daily) was not
beneficial in patients with infective endocarditis and caused exces-
sive bleeding. First, the dose of aspirin that has optimal benefits
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